WallStreetZenWallStreetZen

NASDAQ: MNOV
Medicinova Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MNOV

Based on 3 analysts offering 12 month price targets for Medicinova Inc

Min Forecast
$6.00+354.55%
Avg Forecast
$8.33+531.29%
Max Forecast
$10.00+657.58%

Should I buy or sell MNOV stock?

Based on 3 analysts offering ratings for Medicinova Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MNOV stock forecasts and price targets.

MNOV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-04
lockedlocked$00.00+00.00%2026-03-23
lockedlocked$00.00+00.00%2026-03-16

1 of 1

Forecast return on equity

Is MNOV forecast to generate an efficient return?

Company
242.06%
Industry
94.37%
Market
175.99%
MNOV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MNOV forecast to generate an efficient return on assets?

Company
223.37%
Industry
27.62%
MNOV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MNOV earnings per share forecast

What is MNOV's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.27
Avg 2 year Forecast
-$0.38
Avg 3 year Forecast
$0.08

MNOV revenue forecast

What is MNOV's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$233.6k-60.85%
Avg 2 year Forecast
$408.0k-31.62%
Avg 3 year Forecast
$43.5M+7,198.19%
MNOV's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MNOV revenue growth forecast

How is MNOV forecast to perform vs Biotechnology companies and vs the US market?

Company
292.72%
Industry
34.07%
Market
14.06%
MNOV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MNOV's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MNOV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MNOV$1.32$8.33+531.29%Strong Buy
EDSA$7.35N/AN/A
MCRB$6.61$22.00+232.83%Strong Buy
BYSI$1.61N/AN/A
CING$4.99$28.67+474.49%Strong Buy
View Top Biotech Stocks

Medicinova Stock Forecast FAQ

Is Medicinova Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: MNOV) stock is to Strong Buy MNOV stock.

Out of 3 analysts, 2 (66.67%) are recommending MNOV as a Strong Buy, 1 (33.33%) are recommending MNOV as a Buy, 0 (0%) are recommending MNOV as a Hold, 0 (0%) are recommending MNOV as a Sell, and 0 (0%) are recommending MNOV as a Strong Sell.

If you're new to stock investing, here's how to buy Medicinova stock.

What is MNOV's earnings growth forecast for 2026-2028?

(NASDAQ: MNOV) Medicinova's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.05%.

Medicinova's earnings in 2026 is -$11,720,095.On average, 5 Wall Street analysts forecast MNOV's earnings for 2026 to be -$13,053,474, with the lowest MNOV earnings forecast at -$12,541,573, and the highest MNOV earnings forecast at -$13,437,400. On average, 4 Wall Street analysts forecast MNOV's earnings for 2027 to be -$18,827,127, with the lowest MNOV earnings forecast at -$20,741,833, and the highest MNOV earnings forecast at -$16,538,339.

In 2028, MNOV is forecast to generate $4,016,454 in earnings, with the lowest earnings forecast at -$6,270,787 and the highest earnings forecast at $14,987,869.

What is MNOV's revenue growth forecast for 2026-2028?

(NASDAQ: MNOV) Medicinova's forecast annual revenue growth rate of 292.72% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.

Medicinova's revenue in 2026 is $596,641.On average, 5 Wall Street analysts forecast MNOV's revenue for 2026 to be $11,497,099, with the lowest MNOV revenue forecast at $0, and the highest MNOV revenue forecast at $25,841,154. On average, 4 Wall Street analysts forecast MNOV's revenue for 2027 to be $20,082,268, with the lowest MNOV revenue forecast at $0, and the highest MNOV revenue forecast at $41,345,847.

In 2028, MNOV is forecast to generate $2,143,289,936 in revenue, with the lowest revenue forecast at $1,166,395,866 and the highest revenue forecast at $3,162,957,268.

What is MNOV's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: MNOV) forecast ROA is 223.37%, which is higher than the forecast US Biotechnology industry average of 27.62%.

What is MNOV's Price Target?

According to 3 Wall Street analysts that have issued a 1 year MNOV price target, the average MNOV price target is $8.33, with the highest MNOV stock price forecast at $10.00 and the lowest MNOV stock price forecast at $6.00.

On average, Wall Street analysts predict that Medicinova's share price could reach $8.33 by May 4, 2027. The average Medicinova stock price prediction forecasts a potential upside of 531.29% from the current MNOV share price of $1.32.

What is MNOV's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: MNOV) Medicinova's current Earnings Per Share (EPS) is -$0.23. On average, analysts forecast that MNOV's EPS will be -$0.27 for 2026, with the lowest EPS forecast at -$0.25, and the highest EPS forecast at -$0.27. On average, analysts forecast that MNOV's EPS will be -$0.38 for 2027, with the lowest EPS forecast at -$0.42, and the highest EPS forecast at -$0.34. In 2028, MNOV's EPS is forecast to hit $0.08 (min: -$0.13, max: $0.30).

What is MNOV's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: MNOV) forecast ROE is 242.06%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.